StreetInsider.com News Articles

Form 8-K DYADIC INTERNATIONAL For: May 28

Thu, 28 May 2026 09:11:00 -0400

si-local-file:///var/storage/secattach/20260528/26562379.html

Form 8-K DYADIC INTERNATIONAL For: May 28

Thu, 28 May 2026 09:11:00 -0400

si-local-file:///var/storage/secattach/20260528/26562379.html

Dyadic (DYAI) and Scripps Research Collaborate on Hantavirus Antibody and Vaccine

Thu, 28 May 2026 07:28:25 -0400

Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical applications, today announced that Dyadic Applied BioSolutions and researchers at Scripps Research are collaborating to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus, a hantavirus strain associated with Hantavirus Pulmonary Syndrome (HPS), a severe and potentially fatal respiratory disease in humans.

A series of recently reported hantavirus and Ebola cases worldwide have underscored the importance of pandemic

Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

Thu, 28 May 2026 07:25:00 -0400

Collaboration Leverages Prior Andes, Marburg and Ebola Virus Research and Dyadic’s C1 Platform Capabilities for Fast, Scalable Biologic Production

JUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical applications, today announced that Dyadic Applied BioSolutions and researchers at Scripps Research are collaborating to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus, a hantavirus strain associated with

Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

Thu, 28 May 2026 07:25:00 -0400

Collaboration Leverages Prior Andes, Marburg and Ebola Virus Research and Dyadic’s C1 Platform Capabilities for Fast, Scalable Biologic Production

Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Thu, 21 May 2026 16:05:00 -0400

JUPITER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.

Company Webcast

The webcast presentation will take place at 10:30 a.m. ET on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at

Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Thu, 21 May 2026 16:05:00 -0400

Company Webcast

The webcast presentation will take place at 10:30 a.m. ET on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at

Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Thu, 21 May 2026 16:05:00 -0400

Company Webcast

The webcast presentation will take place at 10:30 a.m. ET on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at

Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Thu, 21 May 2026 16:05:00 -0400

Company Webcast

The webcast presentation will take place at 10:30 a.m. ET on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at

Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series™ on Wednesday, May 27 at 12:00 PM ET

Thu, 21 May 2026 15:45:00 -0400

Company invites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series™

New York, NY, May 21, 2026 (GLOBE NEWSWIRE) -- Skyline Corporate Communications Group, LLC (“Skyline”), an investor relations and corporate communications firm headquartered in New York, today announced that Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic”, “the Company”), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, will present at the Skyline Signature Series™ on Wednesday, May 27, 2026.

This will be a live, interactive

Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series™ on Wednesday, May 27 at 12:00 PM ET

Thu, 21 May 2026 15:45:00 -0400

Company invites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series™

This will be a live, interactive

Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference